{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4LuKx6cIDA","lastupdate":"2023-07-31T00:00:00.000Z","update_date":"2023-07-31T00:00:00.000Z","lastModified":"Aug 31, 2024","active":1,"confidence_score":90,"confidence_score_reason":"markets, not claimed","urlname":"neuralight","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$UTxqomJPckR5V92l5dajyBR38FgwO6mNjABn6wWAEsgziHTpxolr2O","name":"NeuraLight","oneliner":"AI-driven Platform for Digitizing Neurology","registrar":"516350998","website":"https://neuralight.ai","careerspage":"https://neuralight.ai/careers","founded_month":2,"founded_year":2021,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/neuralight","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/71674965","instagram":""},"social":["https://twitter.com/neuralight","https://www.linkedin.com/company/71674965"],"flattenedsociallinks":"https://twitter.com/neuralight|https://www.linkedin.com/company/71674965","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":39,"patent":0,"raised":30500000,"stage":"A","public_stage":"A","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Neura-Light","Neura.Light","NeuraLight.ai","Neura Light"],"about":"NeuraLight is building an AI-driven platform to accelerate and improve drug development, monitoring, and care for patients with neurological disorders by using information captured with a standard smartphone or webcam. \r\n\r\nThe companys platform automatically extracts micro-oculometrics, providing objective and sensitive digital markers for neurological disorders. The solution is designed to serve as a robust proxy for currently used endpoints and to ultimately define a new measurement standard, paving the path for precision medicine in neurology.\r\n\r\nNeuraLight is focused on transforming the lives of the billions of people impacted by neurological disorders by digitizing patient evaluation and care. Its vision is a world where neurological disorders can be prevented, diagnosed, and treated effectively so that people can live longer, healthier lives.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"67061ffe-b2fe-4f25-90b5-d12bca5e490a","city":"Tel Aviv-Yafo","type":null,"address":"Tel Aviv, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"UGZ7Qr6IFmBgrktdk5LFlWwSPDOcjDOr074Ahcn9PFeYgT5GXzcPJR","date":"Apr 26, 2023","link":"https://www.medicaldevice-network.com/news/new-assessment-tool-for-als-based-on-abnormal-eye-movements/","source":"www.medicaldevice-network.com","visible":1,"analysis":{"tags":"Medical Technology","company":"NeuraLight","layoffs":"N/A","summary":"NeuraLights software platform, which evaluates eye movement abnormalities, could be used as an assessment tool for patients with amyotrophic lateral sclerosis (ALS), according to research published in the Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration journal. The use of the platform correlated with current gold-standard clinical assessments, making it a viable adjunct assessment tool. The technology can be implemented in clinical trials and also as part of a routine assessment for ALS patients.","partners":"N/A","customers":"ALS Patients","investors":"N/A","confidence":9,"key_topics":["ALS Assessment","Oculometric Platform","NeuraLight","Clinical Trials","ALSFRS-R"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers","acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"QuFxEeSWc89Z5urpUlTdCAgQdPmkumj6H0fNLD0oarjePGucLjZVkK","news_summary":"New assessment tool for ALS based on abnormal eye movements","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"OYObyP49CInElnVGI4dsrxQxWXGqIZjoHmrjw4b7wJMCuHsQ8E7vSY","date":"Aug 31, 2022","link":"https://www.fastcompany.com/90783696/neuralight-is-making-neurological-diagnostics-more-precise","source":"www.fastcompany.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"JSdXhqJzzuWhzVoczydxCPcf3sXhNRXsCWBBcPRg37Pd2ON4KAWzYm","news_summary":"NeuraLight is making neurological diagnostics more precise","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"2442f294-7a1e-4506-9834-6614fd11d1c3","date":"Jul 28, 2022","link":"https://www.calcalistech.com/ctechnews/article/rj06yaktc","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"collaboration","company":"NeuraLight","layoffs":null,"summary":"NeuraLight, an Israeli company that develops biomarkers for neurological diseases, has announced a collaboration with NeuroSense Therapeutics to promote research on degenerative neurological diseases, including ALS. The collaboration involves monitoring patients and sharing data to improve diagnoses and the use of digital biomarkers. NeuraLight recently raised $25 million in funding and this collaboration marks their first clinical trial. ALS is an incurable neurodegenerative disease, and the collaboration aims to develop disease-modifying therapies. The collaboration is seen as a long-term partnership, with future studies planned for Alzheimers and Parkinsons diseases.","partners":["NeuroSense Therapeutics"],"customers":null,"investors":null,"confidence":8,"key_topics":["Neurological diseases","Biomarkers","Collaboration","ALS","Clinical trial"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4tYgqByxTQufQr1THzesH2tsFoqgdx3AJT5jERJ0seV5sEnVDTYirH","news_summary":"NeuroSense Therapeutics and NeuraLight collaborate to detect ALS using AI  CTech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5f75ac44-3066-4bed-aa34-25e61aaae124","date":"May 24, 2022","link":"https://www.geektime.com/neuralight-secures-25-million-series-a/","source":"www.geektime.com","visible":1,"analysis":{"tags":"Investment, Neurological Disorders","company":"NeuraLight","layoffs":"Not mentioned","summary":"NeuraLight, an Israeli startup developing precision medicine for neurological diseases using computer vision and smartphones, has raised $25 million in a Series A funding round. The round was led by Koch Disruptive Technologies, with participation from Breyer Capital, Samsung NEXT, VSC Ventures, and Viz.ai co-founders Chris Mansi and David Golan. The company plans to use the new capital to improve the design of neurological clinical trials, increase the probability of success for novel neurological therapeutics, and usher in a new era of precision medicine for neurology.","partners":"Not mentioned","customers":"Not mentioned","investors":["Koch Disruptive Technologies","Breyer Capital","Samsung NEXT","VSC Ventures","Chris Mansi","David Golan"],"confidence":10,"key_topics":["Series A Funding","Neurological Disorders","Precision Medicine","Computer Vision","Smartphones"],"date_of_event":"24 May 2022","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$25 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZwX7wUggaWAthiUi0QbSyvDeSDKlPNFZaPG1PaQzepXOcYOksxtPua","news_summary":"NeuraLight secures $25 million in Series A","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6354af3e-9fac-445b-be28-e5896d0830ac","date":"Jan 16, 2022","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3927265,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"appointments","company":"NeuraLight","layoffs":null,"summary":"NeuraLight, a company specializing in digitizing neurological insights using AI, has appointed Dr. Gil Shklarski as Scientific Co-founder and Board Observer. Dr. Shklarski, who previously served as CTO of Flatiron Health, will help NeuraLight in its growth phase from Seed to Series A. He believes in the potential of NeuraLights team and technology to transform the lives of people with neurological disorders. NeuraLight launched in October 2021 with a $5.5 million investment co-led by MSAD.vc, Kli Capital, and Tuesday Capital. Dr. Shklarski will work closely with management to define the strategic playbook and execute the commercial aspects as the company prepares for its first clinical trials.","partners":null,"customers":null,"investors":["MSAD.vc","Kli Capital","Tuesday Capital"],"confidence":9,"key_topics":["NeuraLight","Gil Shklarski","Scientific Co-founder","Board Observer","Seed to Series A round"],"date_of_event":"2022-01-16","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$5.5 million","structured_issues":["Management Changes","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sB8QBA4OW8rmniZV1RGlQSW3SHr0FC8wlAfyDhxEvAHKmDbFi2UIvC","news_summary":"NeuraLight appoints Dr. Gil Shklarski as Scientific Co-founder and Board Observer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4c081f85-9f9d-4316-9ba1-0444b2bab5c7","date":"Jan 11, 2022","link":"https://www.israel21c.org/the-answer-to-parkinsons-and-alzheimers-is-all-in-your-eyes/","source":"www.israel21c.org","visible":1,"analysis":{"tags":["neurological disorders","oculometrics","technology","pharmaceutical development","digital endpoints","AI","machine learning","data extraction","privacy compliance","digital biomarkers","investment","FDA clearance","clinical trials","pharma companies"],"company":"Neuralight","layoffs":null,"summary":"Tel Aviv and Austin-based startup Neuralight has launched with a $5.5 million seed investment. The company aims to digitize and automate neurological evaluation and care by developing a technology that can decode data from the eyes. Neuralights platform extracts microscopic eye movement measurements that serve as digital endpoints for neurological disorders. The company plans to sell the data to pharmaceutical companies to accelerate drug development. Neuralights technology has the potential to make drug development for neurological diseases more effective. The company is in conversations with three large pharma companies and hopes to receive FDA clearance by the end of 2022.","partners":null,"customers":null,"investors":["VSC Ventures","Operator Partners","Clover Health","Immunai"],"confidence":9,"key_topics":["Neurological disorders","Oculometrics","Pharmaceutical development","AI","Digital biomarkers"],"date_of_event":"October 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$5.5 million","structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nl2Ta4tl2dTx5LM8JpFJTiTjg8EuTLAbF8YJ3Wl7Zp7zmdF9QoUIaQ","news_summary":"The answer to Parkinson's and Alzheimer's is all in your eyes","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"97173927-61ac-458d-83e8-bc146267537a","date":"Oct 29, 2021","link":"https://www.finsmes.com/2021/10/neuralight-raises-5-5m-in-seed-funding.html","source":"www.finsmes.com","visible":1,"analysis":{"tags":"neurological disorders","company":"NeuraLight","layoffs":null,"summary":"NeuraLight, a company treating neurological disorders by digitizing neurology care, has raised $5.5 million in seed funding. The funding will be used to enhance the lives of people suffering from neurological disorders by digitizing neurological evaluation and care. NeuraLight uses proprietary Computer Vision and Deep Learning algorithms to capture objective and sensitive digital markers to help accelerate drug development and increase the success rates of new drugs. The platform can be integrated into clinical trials and remote settings, improving the patient experience. The companys team includes industry experts and advisors from the pharmaceutical and healthcare sectors.","partners":null,"customers":null,"investors":"MSAD, Kli, Tuesday, Operator Partners, VSC Ventures, angel investors","confidence":9,"key_topics":["NeuraLight","seed funding","neurological disorders","digitizing neurology care","clinical trials"],"date_of_event":"2021-10-29","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$5.5 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"XG9To3Dwp38r5U20Vrn7xqyQPMlcA9miMvjOEfCxJbOIDhTQvCgMeh","news_summary":"NeuraLight Raises $5.5M in Seed Funding - FinSMEs","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b94d9148-4ea0-4cda-88aa-ec59c2cdb81a","date":"Jun 17, 2021","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3910169,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"neurology, startups","company":"Biogen","layoffs":null,"summary":"The FDAs approval of Biogens Alzheimers drug, Aducanumab, presents a significant opportunity for neurology-focused startups to address the challenges in the field. Neurological disorders affect over one billion people worldwide, and the lack of objective measurements has hindered progress in the field. Startups have successfully leveraged AI and machine learning in other medical disciplines, but neurology has lagged behind. The approval of Aducanumab highlights the need for objective and sensitive measurements in neurological drug development. Startups have the potential to introduce novel technologies and biomarkers that can revolutionize neurological treatment. By utilizing advanced computer vision, machine learning, and innovative approaches, startups can provide continuous monitoring and predictive models for neurological disorders. This presents a growth-positive opportunity for companies like NeuraLight, which aims to digitize neurology and transform the lives of people with neurological disorders.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["FDA approval","Alzheimers drug","neurology-focused startups","lack of objective measurement","novel technologies"],"date_of_event":"17.06.21","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tA1kXoLdgCqJbTWs51O9jsJD1i1Ij7KY8QkJO0S8oLgWvXMOiPOMZp","news_summary":"How can startups leverage controversial FDA approval for Alzheimer's drug?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":8,"techcommunityinvolvement":null,"mediagallery":[{"id":"gZjguz36x1EwaVCRTsX3zU5wwdjurggHw6XaYPaHs0CDOJbrtaGqv9","timestamp":"2023-07-31 19:35:08.000000","resources_type":3,"resources_title":"","resources_file_name":"730399321","alt":"","imageurl":"https://vumbnail.com/730399321.jpg","url":"https://vimeo.com/730399321"}],"tags":["degenerative-diseases","alzheimers-disease","video","healthcare-providers","parkinson","deep-learning","automation","pharma-companies","drug-development","computer-vision","diagnostics","signal-processing","artificial-intelligence","multiple-sclerosis","web-platform","digital-healthcare","decision-support","mobile-applications","telemedicine","neurology"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":[],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":9,"lastfunding":"$25M","totalrounds":2,"fundingstage":"A","totalfunding":"$30.5M","publicinvestors":9,"lastpublicfunding":25000000,"totalpublicrounds":2,"totalpublicfunding":30500000},"team":[{"name":"Gil  Shklarski ","email":"gil@neuralight.ai","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAkPjExaAIDA","bounced":false,"claimed":0,"founder":1,"urlname":"gil-shklarski-2","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICQuOa-wggM","position":"Scientific Co-founder & Board Observer","last_name":"Shklarski ","claimtoken":"BTKPp88wp0kbefuotllFkgTa30SL1e7yI20ePFlVf3fI6yIrC7s70f","first_name":"Gil ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/shklarski/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-07-31 19:38:05.000000","initials":"GS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Micha Breakstone","email":"micha@neuralight.ai","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4JuduIsLDA","bounced":false,"claimed":0,"founder":1,"urlname":"micha-breakstone","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg2-fgrAgM","position":"Co-founder & CEO","last_name":"Breakstone","claimtoken":"OFIHbOdY5JTSYPABHLOyoUDpE1DLXf1Qvz0UmtyPjtAWYWywFWmRhC","first_name":"Micha","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/michabreakstone/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-07-31 19:38:07.000000","initials":"MB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Edmund Benami","email":"edmund@neuralight.ai","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4K-v47EIDA","bounced":false,"claimed":0,"founder":1,"urlname":"edmund-benami","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgr6-FwAoM","position":"Co-founder & CTO","last_name":"Benami","claimtoken":"QjQkrWCEVtPF3XikY6N8igYMod0l6Vee7N3pXjk608yPW03WijQTP5","first_name":"Edmund","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/edmund-benami-76aa641b7/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-07-31 19:38:11.000000","initials":"EB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverifydate":"2021-06-29T00:00:00.000Z","crunchbaseid":"neuralight-3df0","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Jenny Sotnik-Talisman","creator_email":"genys30@yahoo.com","createdate":"2021-03-04T00:00:00.000Z","biverification":"Jenny Sotnik-Talisman","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJC8xuvLCQw","date":"May 2022","amount":"$25M","source":"https://www.geektime.com/neuralight-secures-25-million-series-a/","eventtype":"FundingRoundEvent","investment":[{"name":"Koch Disruptive Technologies","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/koch-disruptive-technologies","logokey":"$JLmWojKisHbeyuUTVetokpcTPNUAfWmFYb2m8M3UEwuiQ8fYd6wFgy","tagline":null,"urlname":"/investor_page/koch-disruptive-technologies","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4LqO7r0IDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"c34cda35-162a-42d8-9ad5-b37fce6a15ad","fundingsubtype":"Corporate VC","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$JLmWojKisHbeyuUTVetokpcTPNUAfWmFYb2m8M3UEwuiQ8fYd6wFgy","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Samsung Next TLV","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/samsung-next-tlv","logokey":"$oPD5FTb5fGsUqtq4RH2XKfkNNIWs4LZyPZQsOaIF77uo9mM07tylAX","tagline":null,"urlname":"/investor_page/samsung-next-tlv","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwOPhwoYLDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"33eed8eb-5250-45a9-ace3-4ce807e098fb","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$oPD5FTb5fGsUqtq4RH2XKfkNNIWs4LZyPZQsOaIF77uo9mM07tylAX","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Chris Mansi","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/chris-mansi","logokey":"$nr4xE0otMVPTRYfV3RJgWkxeIld8VG1BYlub5BqnW5TK6rTZlB8OkJ","tagline":"","urlname":"/investor_page/chris-mansi","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJC0wNm7Cww","fundingtype":"Angel","leadpartner":null,"investmentid":"79b1aef5-6e42-4653-98cd-88435952eec2","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$nr4xE0otMVPTRYfV3RJgWkxeIld8VG1BYlub5BqnW5TK6rTZlB8OkJ","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"David Golan","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/david-golan","logokey":"$3ffB4uZsngbG3qROoB5TSrTJgwb73VhhE7ajd9vlH3dng96bQjs3D3","tagline":"","urlname":"/investor_page/david-golan","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDcrtWXCww","fundingtype":"Angel","leadpartner":null,"investmentid":"89090d2f-d897-4a02-899b-ccbf415ce306","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$3ffB4uZsngbG3qROoB5TSrTJgwb73VhhE7ajd9vlH3dng96bQjs3D3","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Breyer Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/breyer-capital","logokey":"$DOsymM8alshdNH6zcUtzdyIuVk1OFPy2R5gu3E8dqSNvi5NNfHabN6","tagline":"","urlname":"/investor_page/breyer-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk8JrZCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"90e476c9-7d42-403d-a132-16157264b076","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$DOsymM8alshdNH6zcUtzdyIuVk1OFPy2R5gu3E8dqSNvi5NNfHabN6","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":25000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDIvYLXCww","date":"Oct 2021","amount":"$5.5M","source":"https://www.finsmes.com/2021/10/neuralight-raises-5-5m-in-seed-funding.html","eventtype":"FundingRoundEvent","investment":[{"name":"MS&AD Ventures","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/ms-ad-ventures","logokey":"$IXqlXSK1WNqVfhLTCpiqpJMV6iLsdOaV04oB7xNAL1Ecygd5VMXrMc","tagline":"","urlname":"/investor_page/ms-ad-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEqKzaCgw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"54b230f4-97d8-464f-8768-ee326f3825f1","fundingsubtype":"Corporate VC","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$IXqlXSK1WNqVfhLTCpiqpJMV6iLsdOaV04oB7xNAL1Ecygd5VMXrMc","leadcaption":"Lead ","followupcaption":""},{"name":"VSC Ventures","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/vsc-ventures","logokey":"$4O5wHlqaWwulqlsFjXNHCgLPcRPfPYH2HVSOUhJfBhYDHxSMHcnTvL","tagline":"","urlname":"/investor_page/vsc-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDIwcmwCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"108da6d3-a3ef-4820-9904-2a677fd6539d","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4O5wHlqaWwulqlsFjXNHCgLPcRPfPYH2HVSOUhJfBhYDHxSMHcnTvL","leadcaption":"","followupcaption":""},{"name":"Operator Partners","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/operator-partners","logokey":"$Nf5VRqRzC4CBFYniqxJkTE0Dto23rwWLVMrPn3Bq0EjroXzjRrYs4i","tagline":null,"urlname":"/investor_page/operator-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4IPog_wLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"895051e5-ca47-4a11-abda-1f27d0aa8dbc","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Nf5VRqRzC4CBFYniqxJkTE0Dto23rwWLVMrPn3Bq0EjroXzjRrYs4i","leadcaption":"","followupcaption":""},{"name":"Kli Capital","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/kli-capital","logokey":"$KL0Llfx259qduejIotAP3m5TREa9DE37BzpFa3LGbSMDaKkicJtvXS","tagline":null,"urlname":"/investor_page/kli-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkJrZsq4JDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"d9b1f1bf-7138-4f94-83e0-effb9c3af54a","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$KL0Llfx259qduejIotAP3m5TREa9DE37BzpFa3LGbSMDaKkicJtvXS","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"2/2021","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"NeuraLight","logourl":"https://storage.googleapis.com/clean-finder-353810/$UTxqomJPckR5V92l5dajyBR38FgwO6mNjABn6wWAEsgziHTpxolr2O","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$UTxqomJPckR5V92l5dajyBR38FgwO6mNjABn6wWAEsgziHTpxolr2O","seoabout":"NeuraLight is building an AI-driven platform to accelerate and improve drug development, monitoring, and care for patients with neurological disorders by u...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Digital Medical Diagnostics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Platforms & Interfaces","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","classificationName":"coretechnology"},{"depth":2,"name":"Software","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Computer Vision","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","classificationName":"coretechnology"},{"depth":2,"name":"Deep Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA>Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA>Computer Vision#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA>Digital Medical Diagnostics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA>Deep Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA/Digital Medical Diagnostics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA|2:>TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA/Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA|1:>TechnologyClassificationModel/Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA|2:>TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA/Computer Vision#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA|2:>TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA/Deep Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Digital Healthcare","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare","children":[{"title":"Digital Medical Diagnostics","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare>Digital Medical Diagnostics"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]},{"title":"Healthcare","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]}],"coreTechnology":[{"title":"Platforms & Interfaces","key":"0-0","path":"TechnologyClassificationModel>Platforms & Interfaces","children":[{"title":"Software","key":"0-0-0","path":"TechnologyClassificationModel>Platforms & Interfaces>Software"}]},{"title":"Artificial Intelligence","key":"0-1","path":"TechnologyClassificationModel>Artificial Intelligence","children":[{"title":"Computer Vision","key":"0-1-0","path":"TechnologyClassificationModel>Artificial Intelligence>Computer Vision"},{"title":"Deep Learning","key":"0-1-1","path":"TechnologyClassificationModel>Artificial Intelligence>Deep Learning"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Digital Medical Diagnostics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Platforms & Interfaces","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","classificationName":"coretechnology"},{"depth":2,"name":"Software","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Computer Vision","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","classificationName":"coretechnology"},{"depth":2,"name":"Deep Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuDl6YLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Digital Healthcare","Digital Medical Diagnostics"],"coreTechnology":["Platforms & Interfaces","Software","Artificial Intelligence","Computer Vision","Deep Learning"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals","Healthcare","Providers"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJC8xuvLCQw","date":"May 2022","amount":"$25M","source":"https://www.geektime.com/neuralight-secures-25-million-series-a/","eventtype":"FundingRoundEvent","investment":[{"name":"Koch Disruptive Technologies","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/koch-disruptive-technologies","logokey":"$JLmWojKisHbeyuUTVetokpcTPNUAfWmFYb2m8M3UEwuiQ8fYd6wFgy","tagline":null,"urlname":"/investor_page/koch-disruptive-technologies","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4LqO7r0IDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"c34cda35-162a-42d8-9ad5-b37fce6a15ad","fundingsubtype":"Corporate VC","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$JLmWojKisHbeyuUTVetokpcTPNUAfWmFYb2m8M3UEwuiQ8fYd6wFgy","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Samsung Next TLV","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/samsung-next-tlv","logokey":"$oPD5FTb5fGsUqtq4RH2XKfkNNIWs4LZyPZQsOaIF77uo9mM07tylAX","tagline":null,"urlname":"/investor_page/samsung-next-tlv","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwOPhwoYLDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"33eed8eb-5250-45a9-ace3-4ce807e098fb","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$oPD5FTb5fGsUqtq4RH2XKfkNNIWs4LZyPZQsOaIF77uo9mM07tylAX","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Chris Mansi","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/chris-mansi","logokey":"$nr4xE0otMVPTRYfV3RJgWkxeIld8VG1BYlub5BqnW5TK6rTZlB8OkJ","tagline":"","urlname":"/investor_page/chris-mansi","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJC0wNm7Cww","fundingtype":"Angel","leadpartner":null,"investmentid":"79b1aef5-6e42-4653-98cd-88435952eec2","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$nr4xE0otMVPTRYfV3RJgWkxeIld8VG1BYlub5BqnW5TK6rTZlB8OkJ","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"David Golan","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/david-golan","logokey":"$3ffB4uZsngbG3qROoB5TSrTJgwb73VhhE7ajd9vlH3dng96bQjs3D3","tagline":"","urlname":"/investor_page/david-golan","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDcrtWXCww","fundingtype":"Angel","leadpartner":null,"investmentid":"89090d2f-d897-4a02-899b-ccbf415ce306","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$3ffB4uZsngbG3qROoB5TSrTJgwb73VhhE7ajd9vlH3dng96bQjs3D3","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Breyer Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/breyer-capital","logokey":"$DOsymM8alshdNH6zcUtzdyIuVk1OFPy2R5gu3E8dqSNvi5NNfHabN6","tagline":"","urlname":"/investor_page/breyer-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk8JrZCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"90e476c9-7d42-403d-a132-16157264b076","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$DOsymM8alshdNH6zcUtzdyIuVk1OFPy2R5gu3E8dqSNvi5NNfHabN6","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":25000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDIvYLXCww","date":"Oct 2021","amount":"$5.5M","source":"https://www.finsmes.com/2021/10/neuralight-raises-5-5m-in-seed-funding.html","eventtype":"FundingRoundEvent","investment":[{"name":"MS&AD Ventures","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/ms-ad-ventures","logokey":"$IXqlXSK1WNqVfhLTCpiqpJMV6iLsdOaV04oB7xNAL1Ecygd5VMXrMc","tagline":"","urlname":"/investor_page/ms-ad-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEqKzaCgw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"54b230f4-97d8-464f-8768-ee326f3825f1","fundingsubtype":"Corporate VC","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$IXqlXSK1WNqVfhLTCpiqpJMV6iLsdOaV04oB7xNAL1Ecygd5VMXrMc","leadcaption":"Lead ","followupcaption":""},{"name":"VSC Ventures","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/vsc-ventures","logokey":"$4O5wHlqaWwulqlsFjXNHCgLPcRPfPYH2HVSOUhJfBhYDHxSMHcnTvL","tagline":"","urlname":"/investor_page/vsc-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgJDIwcmwCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"108da6d3-a3ef-4820-9904-2a677fd6539d","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$4O5wHlqaWwulqlsFjXNHCgLPcRPfPYH2HVSOUhJfBhYDHxSMHcnTvL","leadcaption":"","followupcaption":""},{"name":"Operator Partners","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/operator-partners","logokey":"$Nf5VRqRzC4CBFYniqxJkTE0Dto23rwWLVMrPn3Bq0EjroXzjRrYs4i","tagline":null,"urlname":"/investor_page/operator-partners","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4IPog_wLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"895051e5-ca47-4a11-abda-1f27d0aa8dbc","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Nf5VRqRzC4CBFYniqxJkTE0Dto23rwWLVMrPn3Bq0EjroXzjRrYs4i","leadcaption":"","followupcaption":""},{"name":"Kli Capital","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/kli-capital","logokey":"$KL0Llfx259qduejIotAP3m5TREa9DE37BzpFa3LGbSMDaKkicJtvXS","tagline":null,"urlname":"/investor_page/kli-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkJrZsq4JDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"d9b1f1bf-7138-4f94-83e0-effb9c3af54a","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$KL0Llfx259qduejIotAP3m5TREa9DE37BzpFa3LGbSMDaKkicJtvXS","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}